

Tralokinumab Biosimilar - Anti-IL-13 Antibody - Low endotoxin, Azide free (A323799)

Specifications:

Name: Tralokinumab Biosimilar - Anti-IL-13 Antibody - Low endotoxin, Azide free

Description: Recombinant human monoclonal antibody to IL-13.

Applications: ELISA, FACS, Functional Assay, In Vivo

Reactivity: Human, Mouse

Host: Human

Clonality: Monoclonal

Isotype: IgG4SP - Human IgG4 with S228P mutation

Light Chains: lambda

Conjugate: Unconjugated

Purification: Protein A affinity chromatography.

Concentration: Reconstitution dependent.

Molecular Weight: This antibody has a predicted MW of 144.14 kDa.

Purity: > 95% (by SDS-PAGE and SEC-HPLC).

Product Form: Lyophilized

Reconstitution: Reconstitute with 100µl of sterile double-distilled water to bring antibody to 1mg/ml

concentration. Gently shake to solubilize completely. Do not vortex!

Formulation: Lyophilized from 25mM Histadine, pH 6.2, with 8% Sucrose and 0.01% Tween80.

Storage: Shipped at 4°C. Lyophilized: Store at -20°C to -80°C. Reconstituted: Aliquot and store at


-80°C. Product is stable for one year. Avoid freeze/thaw cycles.

Disclaimer: This product is for research use only. It is not intended for diagnostic or therapeutic use.




Tralokinumab Biosimilar - Anti-IL-13 Antibody - Low endotoxin, Azide free (A323799)

Images:



SDS-PAGE analysis of Tralokinumab Biosimilar - Anti-IL-13 Antibody - Low endotoxin, Azide free (A323799) under reducing (R) conditions confirms that the purity of this antibody is greater than 95%.



SEC-HPLC analysis of Tralokinumab Biosimilar - Anti-IL-13 Antibody - Low endotoxin, Azide free (A323799) confirms that the purity of this antibody is 100%.